This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Nordson (NDSN) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Nordson (NDSN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Buy 5 Large-Cap Stocks Ahead of Earnings Results This Month
by Nalak Das
Expectations for second-quarter earnings as a whole, have improved to some extent from what they were at the beginning of the reporting cycle.
4 Industrial Stocks Set to Beat This Earnings Season
by Madhurima Das
Despite a weak manufacturing sector weighing down on the Industrial Products Sector, we have handpicked four stocks that are poised to beat estimates in the upcoming reporting cycle.
TNC or NDSN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
TNC vs. NDSN: Which Stock Is the Better Value Option?
Why Is Nordson (NDSN) Up 10.7% Since Last Earnings Report?
by Zacks Equity Research
Nordson (NDSN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Xylem (XYL) Declines 19% YTD: What's Affecting the Stock?
by Zacks Equity Research
Xylem (XYL), with shares down 19% so far in 2020, faces risks from difficult end-market conditions due to the pandemic, forex woes and cost inflation. Q2 organic sales are likely to fall 20-30% y/y.
Nordson (NDSN) Buys Fluortek, Strengthens Product Offerings
by Zacks Equity Research
Nordson's (NDSN) buyout of Fluortek will likely enable it to strengthen its product offerings in the medical device market.
Nordson (NDSN) Beats Q2 Earnings Estimates, Withdraws View
by Zacks Equity Research
Nordson's (NDSN) earnings in second-quarter fiscal 2020 benefited from lower costs and expenses, partially offsetting the sales decline. It withdrew fiscal 2020 view due to pandemic worries.
Nordson (NDSN) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Nordson (NDSN) delivered earnings and revenue surprises of 23.44% and 4.13%, respectively, for the quarter ended April 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Nordson (NDSN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Nordson (NDSN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Nordson Displays Bright Prospects Despite Persistent Risks
by Zacks Equity Research
Nordson (NDSN) is poised to gain from strong medical end markets, growth initiatives and buyouts. Weak Advanced Technology Systems segment and high costs remain concerning.
Danaher (DHR) to Report Q1 Earnings: Is a Beat in Store?
by Zacks Equity Research
Danaher's (DHR) Q1 results are expected to reflect healthy segmental growth. However, adverse impacts of the coronavirus outbreak on demand are anticipated to have ailed.
Ball Corp (BLL) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Ball Corp's (BLL) Q1 performance likely to reflect benefits from solid demand for aluminum packaging, cost-cutting actions and robust aerospace backlog.
Illinois Tool (ITW) to Post Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Illinois Tool (ITW) Q1 results are likely to reflect the adverse impacts of the pandemic, forex woes and divestitures despite diversified business, product offering and enterprise strategy.
Xylem (XYL) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Xylem's (XYL) Q1 results are expected to reflect the adverse impacts of the uncertainties caused by the coronavirus outbreak. But healthy balance sheet and cost actions might have aided.
What to Expect for Stanley Black & Decker's (SWK) Q1 Earnings?
by Zacks Equity Research
Stanley Black & Decker's (SWK) first-quarter earnings results are likely to reflect the adverse impacts of the coronavirus outbreak. External woes (forex woes, tariffs and commodity inflation) might have hurt too.
What to Expect For 3M Company (MMM) This Earnings Season?
by Zacks Equity Research
3M Company's (MMM) first-quarter 2020 results are likely to reflect the adverse impacts of measures taken to deal with the coronavirus outbreak. However, huge demand for certain products might aid.
Sharps Compliance (SMED) to Post Q3 Earnings: What to Expect?
by Zacks Equity Research
Sharps Compliance's (SMED) third-quarter fiscal 2020 earnings are likely to reflect gains from the growing popularity of unused medication and route-based businesses. High expenses might have been spoilsport.
Nordson (NDSN) Announces Plan to Reorganize into 2 Businesses
by Zacks Equity Research
Nordson's (NDSN) business realignment will likely help it achieve its long-term priorities. It also intends on bringing its financial reporting on par with the new business structure.
Nordson (NDSN) Gains From Buyouts Despite Segmental Woes
by Zacks Equity Research
Nordson (NDSN) is likely to benefit from strength in its medical product end markets, growth initiatives and buyouts. Weak Advanced Technology Systems segment and high cost of sales remain concerning.
Flowserve Down 59% YTD on Coronavirus & Other Global Woes
by Zacks Equity Research
Flowserve (FLS), with shares down 59% so far in 2020, faces risks from geopolitical and macroeconomic headwinds. The virus outbreak might hurt its China manufacturing operations and supplier networks.
Nordson (NDSN) Down 33.4% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Nordson (NDSN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Applied Industrial (AIT) Declines 52% YTD: What's Hurting it?
by Zacks Equity Research
Applied Industrial (AIT), with shares down 52% so far in 2020, faces headwinds from uncertain end-market conditions. Organic sales performance will likely be weak for both segments throughout the rest of fiscal 2020.
Xylem (XYL) Declines 18% YTD: What's Hurting the Stock?
by Zacks Equity Research
Xylem (XYL), with an 18% decline in shares so far in 2020, faces headwinds from the coronavirus outbreak, softness in commercial and industrial markets, and soft orders.
Altra Industrial (AIMC) Declines 40% YTD: What's Hurting it?
by Zacks Equity Research
Altra Industrial (AIMC), with shares down 40% so far in 2020, faces headwinds from difficult end-market conditions, unfavorable movements in foreign currencies and the coronavirus outbreak.